CUFinder

Matteo Marchesini

About Matteo Marchesini

Matteo Marchesini, With an exceptional h-index of 12 and a recent h-index of 11 (since 2020), a distinguished researcher at Università degli Studi di Parma,

His recent articles reflect a diverse array of research interests and contributions to the field:

Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma

The Atypical Protein Kinase WNK1 Controls Leukemia Progression in TAL/LMO T-Cell Acute Lymphoblastic Leukemia

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Novel Mechanisms of Venetoclax Resistance in Acute Myeloid Leukemia Based on Genomic Rearrangements

P-057 Role of the combination of FDG-PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: a prospective trial

P-056 Role the combination of FDG pet plus whole body MRI for staging patients in high risk smoldering myeloma: a prospective trial

MM-602 Role of the Combination of FDG-PET Plus Whole Body MRI for Staging Patients With High-Risk Smoldering Myeloma: A Prospective Trial

MM-638 Role of the Combination of FDG-PET plus Whole Body MRI for Staging Newly Diagnosed and Relapsed/Refractory Multiple Myeloma (MM): A Prospective Trial

Matteo Marchesini Information

University

Position

___

Citations(all)

1744

Citations(since 2020)

1191

Cited By

1074

hIndex(all)

12

hIndex(since 2020)

11

i10Index(all)

12

i10Index(since 2020)

12

Email

University Profile Page

Google Scholar

Top articles of Matteo Marchesini

Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma

Nature Communications

2024/2/8

Natalia Baran
Natalia Baran

H-Index: 1

Pamela Lockyer
Pamela Lockyer

H-Index: 14

Christopher Jackson
Christopher Jackson

H-Index: 1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Rodrigo Fonseca
Rodrigo Fonseca

H-Index: 27

Lin Tan
Lin Tan

H-Index: 8

Nicola Giuliani
Nicola Giuliani

H-Index: 4

Andrea Santoni
Andrea Santoni

H-Index: 10

Koichi Takahashi
Koichi Takahashi

H-Index: 15

Andrea Viale
Andrea Viale

H-Index: 4

The Atypical Protein Kinase WNK1 Controls Leukemia Progression in TAL/LMO T-Cell Acute Lymphoblastic Leukemia

Blood

2023/11/28

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Luca Pagliaro
Luca Pagliaro

H-Index: 2

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Blood

2023/11/28

Anna Ferrari
Anna Ferrari

H-Index: 0

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Novel Mechanisms of Venetoclax Resistance in Acute Myeloid Leukemia Based on Genomic Rearrangements

Blood

2023/11/2

Anna Ferrari
Anna Ferrari

H-Index: 0

Jacopo Nanni
Jacopo Nanni

H-Index: 9

Matteo Paganelli
Matteo Paganelli

H-Index: 1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

P-057 Role of the combination of FDG-PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: a prospective trial

Clinical Lymphoma Myeloma and Leukemia

2023/9/1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Alice Rossi
Alice Rossi

H-Index: 2

P-056 Role the combination of FDG pet plus whole body MRI for staging patients in high risk smoldering myeloma: a prospective trial

Clinical Lymphoma Myeloma and Leukemia

2023/9/1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Alice Rossi
Alice Rossi

H-Index: 2

MM-602 Role of the Combination of FDG-PET Plus Whole Body MRI for Staging Patients With High-Risk Smoldering Myeloma: A Prospective Trial

Clinical Lymphoma Myeloma and Leukemia

2023/9/1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Alice Rossi
Alice Rossi

H-Index: 2

MM-638 Role of the Combination of FDG-PET plus Whole Body MRI for Staging Newly Diagnosed and Relapsed/Refractory Multiple Myeloma (MM): A Prospective Trial

Clinical Lymphoma Myeloma and Leukemia

2023/9/1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Alice Rossi
Alice Rossi

H-Index: 2

P451: GENE FUSIONS AND OTHER GENOMIC EVENTS UNDERLIE VENETOCLAX AND HYPOMETHYLATING AGENT RESISTANCE AND PROVIDE NEW TARGETS IN ACUTE MYELOID LEUKEMIA.

HemaSphere

2023/8/1

Anna Ferrari
Anna Ferrari

H-Index: 0

Jacopo Nanni
Jacopo Nanni

H-Index: 9

Matteo Paganelli
Matteo Paganelli

H-Index: 1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

P953: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL

HemaSphere

2023/8/1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Alice Rossi
Alice Rossi

H-Index: 2

P918: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL

HemaSphere

2023/8/1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Alice Rossi
Alice Rossi

H-Index: 2

P-206 3D in vitro modelling of relapsed/refractory multiple myeloma to unveil mechanisms of acquired resistance to therapy

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

2023

Matteo Paganelli
Matteo Paganelli

H-Index: 1

Alessandro De Vita
Alessandro De Vita

H-Index: 24

Alice Rossi
Alice Rossi

H-Index: 2

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia

Cell Death & Disease

2022/6/17

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Luca Pagliaro
Luca Pagliaro

H-Index: 2

Linda Ross
Linda Ross

H-Index: 14

Gabriela Alexe
Gabriela Alexe

H-Index: 34

Yan Xiong
Yan Xiong

H-Index: 3

Jian Jin
Jian Jin

H-Index: 1

Federico Quaini
Federico Quaini

H-Index: 33

Paolo Sportoletti
Paolo Sportoletti

H-Index: 24

Addition of carfilzomib as a third agent in lenalidomide-refractory multiple myeloma: Switching from doublet to triplet.

2022/6/1

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

Nature medicine

2022/3

Hui Yang
Hui Yang

H-Index: 6

Feng Wang
Feng Wang

H-Index: 17

Pamela Lockyer
Pamela Lockyer

H-Index: 14

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Nicola Giuliani
Nicola Giuliani

H-Index: 4

Matteo Pellegrini
Matteo Pellegrini

H-Index: 68

Jing Wang
Jing Wang

H-Index: 18

Jason Walker
Jason Walker

H-Index: 24

Ziyi Li
Ziyi Li

H-Index: 1

Koichi Takahashi
Koichi Takahashi

H-Index: 15

Identification of the Atypical Protein Kinase WNK1 As a New Target in T-Cell Acute Lymphoblastic Leukemia

Blood

2022/11/15

Luca Pagliaro
Luca Pagliaro

H-Index: 2

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML

Blood

2022/11/15

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Luca Pagliaro
Luca Pagliaro

H-Index: 2

Federico Quaini
Federico Quaini

H-Index: 33

MM-498 Addition of Carfilzomib as a Third Agent in Lenalidomide-Refractory Multiple Myeloma: Switching From Doublet to Triplet

Clinical Lymphoma Myeloma and Leukemia

2022/10/1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

Fabrizio Pane
Fabrizio Pane

H-Index: 41

MM-501 Domestic Opportunity in Heavily Pretreated Multiple Myeloma Not Eligible for Hospital-Based Treatment: Role of Pomalidomide-Dexamethasone

Clinical Lymphoma Myeloma and Leukemia

2022/10/1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

P-184: Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone

Clinical Lymphoma Myeloma and Leukemia

2022/8/1

Matteo Marchesini
Matteo Marchesini

H-Index: 9

See List of Professors in Matteo Marchesini University(Università degli Studi di Parma)